Pioneering a breakthrough in metabolic medicine through the targeted inhibition of the INDY gene.

Eternygen is an asset centric drug discovery and development company focusing on small molecule INDY inhibitors. INDY is one of the most attractive novel targets for treatment of metabolic diseases. INDY blocking drugs have blockbuster potential since dietary-related metabolic diseases (like obesity, non-alcoholic fatty liver disease (NAFLD/NASH) and type-2 diabetes) are increasing globally and still cannot be treated in an optimal way. Eternygen has a leading position in the development of INDY blocking agents.